Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.54 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.54 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.54 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 15/20 | 0.49 |
| ▸ | GSK3A | P49840 | 15/20 | 0.49 |
| ▸ | SYK | P43405 | 14/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5623634 | 0.96 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11SRC | |
| SCHEMBL5622531 | 0.94 | GSK3A (0.47) | MAPK14MAPK13MAPK12MAPK11SRC | |
| SCHEMBL5622560 | 0.90 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11SRC | |
| SCHEMBL8271233 | 0.89 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11SRC | |
| SCHEMBL13941144 | 0.88 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11SRC | |
| SCHEMBL6305403 | 0.88 | GSK3A (0.58) | MAPK14MAPK13MAPK12MAPK11SRC | |
| SCHEMBL5623931 | 0.88 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11SRC | |
| SCHEMBL5623330 | 0.86 | GSK3A (0.47) | MAPK14MAPK12SRCGSK3ASYK | |
| SCHEMBL5623611 | 0.86 | HSP90AA1 (0.46) | MAPK14MAPK13MAPK12MAPK11GSK3A | |
| SCHEMBL5622047 | 0.85 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116245-A2 | EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | disclosed |
| US-7279475-B2 | Fluorinated di-aryl urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279475-B2 | Fluorinated di-aryl urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279475-B2 | Fluorinated di-aryl urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-6872726-B2 | Fluorinated di-aryl urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-03-29 | — | — | US | disclosed |
| WO-2005018624-A2 | METHODS OF TREATING COPD AND PULMONARY HYPERTENSION | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050032797-A1 | Fluorinated di-aryl urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| US-20040077647-A1 | Cytokine inhibitors, antiinflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077647-A1 | Cytokine inhibitors, antiinflammatory agents | IL1B, IL1A, TNF | MAPK14 1398/4885MAPK13 1911/4885MAPK12 1832/4885 |
| US-20050032797-A1 | Fluorinated di-aryl urea compounds | IL1B, MPO, IL1A | MAPK14 1915/4885MAPK13 1694/4885MAPK12 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.